Previous close | 0.0200 |
Open | 0.0200 |
Bid | 0.0000 |
Ask | 0.5000 |
Strike | 4.50 |
Expiry date | 2023-04-21 |
Day's range | 0.0200 - 0.0200 |
Contract range | N/A |
Volume | |
Open interest | 454 |
MALVERN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 at the Ritz Carlton, Laguna Niguel in Dana Point, Cal
MALVERN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced the appointment of Quan A. Vu to Chief Financial Officer & Chief Business Officer. “Quan has quickly become a tremendous asset for Ocugen and his comprehensive healthcare and financial expertise is providing valuable insight toward reaching our c
With the business potentially at an important milestone, we thought we'd take a closer look at Ocugen, Inc.'s...